Reported 2 months ago
GLP-1 weight-loss medications could be valued at $500 billion by 2030, driven by rising obesity rates and expanding treatment applications. Tema ETFs CEO Maurits Pot highlights that with a projected increase in users from 2% to 20% of the global population, coupled with a significant price drop, the market is set for substantial growth. Investors are encouraged to pay attention to companies in this sector.
Source: YAHOO